Truvada Articles
New Zealand to fund Gilead's Atripla and Truvada
27 November 2012
Gilead HIV drugs Atripla and Truvada to be listed in New Zealand
13 November 2012
FDA approves Truvada, first drug for reducing the risk of sexually acquired HIV infection
17 July 2012
New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada
10 June 2012
US FDA priority review for Truvada for reducing HIV risk
15 February 2012
Gilead filing of Truvada for PrEP looks contentious
19 December 2011
AHF lambasts Gilead over HIV drug price hikes
6 April 2011
US FDA grants pediatric exclusivity for Sanofi/B-MS Plavix; rejects Gilead’s filing for combination AIDS pill
26 January 2011
Breakthrough research shows Gilead antiretroviral Truvada can prevent HIV in men who have sex with men
24 November 2010
J&J posts higher first-quarter 2010 profit, boosted by one-time gain, but lowers forecast; updates on Truvada combo n HIV
21 April 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Gilead files 2nd patent suit against Teva
15 May 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Gilead presents HIV drug-booster at CROI
16 February 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
Gilead files patent suit against Teva
22 December 2008
Teva challenges two of Gilead's Truvada patents
24 November 2008
Gilead up almost 30% on HIV franchise
27 October 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
GSK's Epzicom comparable to Truvada
18 August 2008
Gilead leads in selling Atripla in new countries
11 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
HIV/AIDS drug prices frozen for US agencies
9 June 2008
Gilead record sales push revenue up 22%
28 April 2008
India NGOs at war with cancer drug patents
7 April 2008
Stock Commentary - New York week to March 3, 2008
10 March 2008
VERXVE study to test once-daily Viramune
18 February 2008
Stock Commentary - New York week to Jan 28, 2008
4 February 2008
Boeh Ingl initiates US Viramune study
10 December 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Atripla approved in Canada for HIV-1
22 October 2007
Strong data for Prezista HIV regimen
1 October 2007
Small number of combination drugs reaching the Japanese market
24 September 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
Gilead's share price up on strong 4th-qtr sales
12 February 2007
Gilead subpoenaed over HIV drugs
18 December 2006
Invirase lowers HIV levels with better lipid profile
20 November 2006
Stock Commentary - New York week to Oct 16, 2006
23 October 2006
Israeli basket update c'tee recommends another 16 new technologies
4 September 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Gilead's 1st-qtr sales reach $692.9M, up 61%
15 May 2006
B-MS and Gilead enter deal for HAART tablet
8 May 2006
Gilead reports $2B revenue in 2005, up 53%
6 February 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
Gilead/B-MS' HIV combo drug is bioequivalant
16 January 2006
Stock Commentary - New York week to Jan 9
16 January 2006
Gilead cuts Viread, Truvada prices to LDCs
5 September 2005
Gilead's Truvada fails bioequivalence study
22 August 2005
Stock Commentary - New York week to Aug 15
22 August 2005
Gilead's Truvada HIV combo not bioequivalent
15 August 2005
Gilead's 2nd-qtr revenues up 55%
1 August 2005
Gilead Sci/Aspen in marketing deal
16 May 2005
Truvada lifts 1st qtr for Gilead Sciences
25 April 2005
Truvada get EU market approval
7 March 2005
Gilead reports 48-wk data from HIV study
14 February 2005
B-MS and Gilead set up JV to market triple AIDS drugs
10 January 2005
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
US FDA clears way for Gilead's Truvada
9 August 2004
Showing 1-79 of 79 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
